Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers

Stem Cells

Volumn 30, Issue 7, 2012, Pages 1338-1348

  Stratford, Anna L ^a   Reipas, Kristen ^a   Hu, Kaiji ^a   Fotovati, Abbas ^a   Brough, Rachel ^b,c   Frankum, Jessica ^c   Takhar, Mandeep ^a   Watson, Peter ^d   Ashworth, Alan ^b,c   Lord, Christopher J ^c   Lasham, Annette ^e   Print, Cristin G ^e   Dunn, Sandra E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

CD44; Ribosomal S6 kinase; Therapeutic target; Tumor initiating cells; Y box binding protein 1

Indexed keywords

ALPHA6 INTEGRIN; BI D1870; HERMES ANTIGEN; MESSENGER RNA; PROTEIN P90; PROTEIN SERINE THREONINE KINASE INHIBITOR; S6 KINASE; SL 0101; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; Y BOX BINDING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CELL DEATH; CELL GROWTH; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EX VIVO STUDY; FEMALE; GENE SILENCING; HUMAN; HUMAN TISSUE; MITOSIS; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN TARGETING; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; ANTIGENS, CD44; APOPTOSIS; BENZOPYRANS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MONOSACCHARIDES; PROMOTER REGIONS, GENETIC; PTERIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; Y-BOX-BINDING PROTEIN 1;

MUS;

EID: 84862868502     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1128     Document Type: Article

References (50)

1. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007;13: 4429-4434. (Pubitemid 47219710)
2. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-1281.
3. Honeth G, Bendahl PO, Ringnér M et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008;10:R53.
4. Charafe-Jauffret E, Ginestier C, Iovino F et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009;69:1302-1313.
5. Nakshatri H, Srour EF, Badve S. Breast cancer stem cells and intrinsic subtypes: Controversies rage on. Curr Stem Cell Res Ther 2009;4: 50-60.
6. Park SY, Lee HE, Li H et al. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 2010;16:876-887.
7. Creighton CJ, Li X, Landis M et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009;106:13820-13825.
8. Li X, Lewis MT, Huang J et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100: 672-679.
9. Phillips TM, McBride WH, Pajonk F. The response of CD24-/low/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006;98:1777-1785. (Pubitemid 46017929)
10. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; 10:R25.
11. To K, Fotovati A, Reipas KM et al. YB-1 induces expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res 2010;70:2840-2851.
12. Stratford AL, Reipas K, Maxwell C et al. Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer. Expert Rev Mol Med 2010;12:e22.
13. Dontu G, Wicha MS. Survival of mammary stem cells in suspension culture: Implications for stem cell biology and neoplasia. J Mammary Gland Biol Neoplasia 2005;10:75-86. (Pubitemid 40724024)
14. Ponti D, Costa A, Zaffaroni N et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005;65:5506-5511. (Pubitemid 40911148)
15. Murohashi M, Hinohara K, Kuroda M et al. Gene set enrichment analysis provides insight into novel signalling pathways in breast cancer stem cells. Br J Cancer 2010;102:206-212.
16. Blick T, Hugo H, Widodo E et al. Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia 2010;15:235-252.
17. Shipitsin M, Campbell LL, Argani P et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007;11:259-273. (Pubitemid 46349843)
18. Sawyers CL. Lessons learned from the development of kinase inhibitors. Clin Adv Hematol Oncol 2009;7:588-589.
19. Carriere A, Ray H, Blenis J et al. The RSK factors of activating the Ras/MAPK signaling cascade. Front Biosci 2008;13:4258-4275. (Pubitemid 351611599)
20. Kang S, Dong S, Gu TL et al. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell 2007;12: 201-214. (Pubitemid 47333416)
21. Law JH, Habibi G, Hu K et al. Phosphorylated insulin-like growth factor-1/insulin receptor is present in all breast cancersubtypes and is related to poor survival. Cancer Res 2008;68:10238-10246.
22. Stratford AL, Fry CJ, Desilets C et al. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res 2008;10:R99.
23. Anjum R, Blenis J. The RSK family of kinases: Emerging roles in cellular signalling. Nat Rev Mol Cell Biol 2008;9:747-758.
24. Chen R-H, Abate C, Blenis J. Phosphorylation of the c-Fos transrepression domain by mitogen-activated protein kinase and 90-kDa ribosomal S6 kinase. Proc Natl Acad Sci USA 1993;90:10952-10956. (Pubitemid 23354346)
25. Shimamura A, Ballif BA, Richards SA et al. Rsk1 mediates a MEK-MAP kinase cell survival signal. Curr Biol 2000;10:127-135. (Pubitemid 30115743)
26. Sutherland C, Leighton IA, Cohen P. Inactivation of glycogen synthase kinase-3 β by phosphorylation: New kinase connections in insulin and growth-factor signalling. Biochem J 1993;296:15-19. (Pubitemid 23344723)
27. Lau PNL, Cheung P. Histone code pathway involving H3 S28 phosphorylation and K27 acetylation activates transcription and antagonizes polycomb silencing. Proc Natl Acad Sci USA 2011;108: 2801-2806.
28. Sassone-Corsi P, Mizzen CA, Cheung P et al. Requirement of RSK2 for epidermal growth factor-activated phosphorylation of histone H3. Science 1999;285:886-891. (Pubitemid 29381988)
29. To K, Zhao Y, Jiang H et al. The phosphoinositide-dependent kinase-1 inhibitor, OSU03012, prevents Y-box binding protein-1 (YB-1) from inducing epidermal growth factor receptor (EGFR). Mol Pharmacol 2007;72:641-652. (Pubitemid 47347299)
30. Smith JA, Poteet-Smith CE, Xu Y et al. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res 2005;65: 1027-1034. (Pubitemid 40216465)
31. Brough R, Frankum JR, Sims D et al. Functional viability profiles of breast cancer. Cancer Discov 2011;1:260-273.
32. Wu J, Lee C, Yokom D et al. Disruption of the Y-Box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res 2006;66:4872-4879.
33. Lasham A, Samuel W, Cao H et al. YB-1, the E2F pathway, and regulation of tumor cell growth. J Natl Cancer Inst 2012;104:1-14.
34. Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biometrika 1982;69:553-566.
35. Desmedt C, Piette F, Loi S et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007;13:3207-3214. (Pubitemid 46944903)
36. Law JH, Li Y, To K et al. Molecular decoy to the Y-box binding protein- 1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability. PLoS One 2010;5:e12661.
37. Calcagno AM, Salcido CD, Gillet J-P et al. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst 2010;102:1637-1652.
38. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-1948.
39. Habibi G, Leung S, Law JH et al. Re-defining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res 2008;10:R86.
40. Davies AH, Barrett I, Pambid MR et al. YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification. Oncogene 2011;30:3649-3660.
41. Fotovati A, Abu-Ali S, Wang PS et al. YB-1 bridges neural stem cells and brain-tumor initiating cells via its roles in differentiation and cell growth. Cancer Res 2011;71:5569-5578.
42. Shiota M, Takeuchi A, Song Y et al. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression. Endocr Relat Cancer 2011;18:505-517.
43. Hamilton SR, Fard SF, Paiwand FF et al. The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem 2007;282: 16667-16680. (Pubitemid 47100370)
44. Kang S, Elf S, Dong S et al. Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformation. Mol Cell Biol 2009;29:2105-2117.
45. Jin L, Hope KJ, Zhai Q et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006;12:1167-1174. (Pubitemid 44527352)
46. Patrawala L, Calhoun-Davis T, Schneider-Broussard R et al. Hierarchical organization of prostate cancer cells in xenograft tumors: The CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res 2007;67:8973.
47. Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030-1037.
48. Dalerba P, Dylla SJ, Park IK et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104:10158-10163. (Pubitemid 47175279)
49. Stratford AL, Dunn SE. The promise and challenges of targeting RSK for the treatment of cancer. Expert Opin Ther Targets 2011;15:1-4.
50. Kang S, Elf S, Lythgoe K et al. p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J Clin Invest 2010;120:1165-1177.